<DOC>
	<DOCNO>NCT01588769</DOCNO>
	<brief_summary>It primary objective study show safety tolerability administration cell base immunotherapy ALECSAT patient Glioblastoma brain cancer . It secondary objective establish indication positive therapeutic palliative effect may observe .</brief_summary>
	<brief_title>A Phase I Study Investigate Tolerability Efficacy ALECSAT Administered Glioblastoma Multiforme Patients</brief_title>
	<detailed_description>The primary objective study establish side effect toxicity issue occur , prevent clinical development autologous cell base immunotherapy ALECSAT Glioblastoma ( GBM ) establish side effect toxicity issue , suggest clinical development plan , change course significantly . It primary objective show safety tolerability administration ALECSAT , thus meet endpoint , may stop clinical development ALECSAT . The secondary objective study establish indication positive therapeutic palliative effect may observe . As secondary objective , observe significant positive clinical effect , prevent clinical development , trigger change clinical development plan . The overall endpoint study develop new therapeutic approach may slow stop disease progression late stage GBM patient . ALECSAT autologous cell base immunotherapy base patient 's Natural Killer cell CytoToxic T cell . The cell isolate patient 's blood - activate expanded number administer i. v .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Recurrence GBM tumour document MRI PET patient receive available standard treatment . 2 . Be age 18 capable understanding information give informed consent . 3 . Adequate performance status &gt; 50 % ( see below* ) . Performance monitor accord Karnofsky Performance Score ( KPS ) 100 % normal , complaint , sign disease 90 % capable normal activity , symptom sign disease 80 % normal activity difficulty , symptom sign 70 % care self , capable normal activity work 60 % require help , take care personal requirement 50 % require help often , require frequent medical care 40 % disabled , require special care help 30 % severely disabled , hospital admission indicate risk death 20 % ill , urgently require admission , require supportive measure treatment 10 % moribund , rapidly progressive fatal disease process 0 % death . 1 . A low blood count ( haemoglobin &lt; 6.0 mmol/l ) . 2 . Lymphocyte count 0.8 x 109/l . 3 . Positive test antiHIV1/2 ; 4 . Positive test HBsAg , 5 . Positive test antiHBc AntiHCV . 6 . Syphilis i.e . positive Treponema Pallidum test . 7 . Uncontrolled serious bacterial , viral , fungal parasitic infection . 8 . Clinically significant autoimmune disorder condition immune suppression . 9 . Treatment chemotherapy three week prior inclusion clinical trial . 10 . Pregnant woman include trial . Fertile woman include negative pregnancy test must use contraceptive study . 11 . Blood transfusion within 48 hour prior donation blood ALECSAT production . 12 . Inclusion clinical trial 6 week prior inclusion trial . 13 . The patient 's medical condition evaluate poor significant risk patient part trial evaluate effect treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Brain cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cell base therapy</keyword>
	<keyword>Autologous cell base therapy</keyword>
	<keyword>Adoptive immunotherapy</keyword>
	<keyword>Cytotoxic T cell</keyword>
	<keyword>Natural Killer cell</keyword>
</DOC>